We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+33.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.72B
AUM Growth
-$71.4M
Cap. Flow
-$452M
Cap. Flow %
-16.6%
Top 10 Hldgs %
41.91%
Holding
86
New
16
Increased
22
Reduced
27
Closed
9

Top Buys

Rank Stock Value
1
SLN
Silence Therapeutics
SLN
+$44.1M
2
KROS icon
Keros Therapeutics
KROS
+$32.8M
3
FDMT icon
4D Molecular Therapeutics
FDMT
+$32.2M
4
CI icon
Cigna
CI
+$21.5M
5
IMNM icon
Immunome
IMNM
+$20.5M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$487M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$115M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$67.7M
4
KRYS icon
Krystal Biotech
KRYS
+$31.2M
5
CTLT
CATALENT, INC.
CTLT
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.54%
2 Industrials 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
51
DELISTED
Ventyx Biosciences
VTYX
$11.9M 0.44%
2,164,126
+1,956,923
+944% +$8.95M
ISRG icon
52
Intuitive Surgical
ISRG
$122B
$11.8M 0.43%
29,546
-24,712
-46% -$9.34M
CYTK icon
53
Cytokinetics
CYTK
$10.9B
$11.3M 0.42%
+161,600
New +$12.5M
DGX icon
54
Quest Diagnostics
DGX
$23.3B
$11.2M 0.41%
+83,849
New +$10.9M
MCK icon
55
McKesson
MCK
$98.5B
$11.1M 0.41%
+20,707
New +$10.5M
NUVB icon
56
Nuvation Bio
NUVB
$2.02B
$11M 0.4%
3,031,009
– –
ELAN icon
57
Elanco Animal Health
ELAN
$12.9B
$11M 0.4%
+676,039
New +$10.6M
BPMC
58
DELISTED
Blueprint Medicines
BPMC
$10.7M 0.39%
+113,060
New +$9.7M
PEN icon
59
Penumbra
PEN
$12.5B
$9.96M 0.37%
44,613
-50,629
-53% -$12.5M
RPTX
60
DELISTED
Repare Therapeutics
RPTX
$9.5M 0.35%
2,016,302
-132,446
-6% -$849K
APLS
61
DELISTED
Apellis Pharmaceuticals
APLS
$9.11M 0.33%
+155,000
New +$9.88M
STXS icon
62
Stereotaxis
STXS
$154M
$8.64M 0.32%
3,308,798
-93,645
-3% -$223K
CABA icon
63
Cabaletta Bio
CABA
$461M
$7.55M 0.28%
442,826
-931,363
-68% -$20M
LVTX
64
DELISTED
LAVA Therapeutics
LVTX
$6.91M 0.25%
2,074,372
– –
ATRA icon
65
Atara Biotherapeutics
ATRA
$75.6M
$6.43M 0.24%
370,532
+6,274
+2% +$111K
IVVD icon
66
Invivyd
IVVD
$219M
$6.4M 0.23%
1,440,725
– –
RAPT
67
DELISTED
RAPT Therapeutics
RAPT
$5.95M 0.22%
82,800
+36,953
+81% +$5.14M
ACIU icon
68
AC Immune
ACIU
$224M
$5.94M 0.22%
2,007,031
+7,031
+0.4% +$25.2K
ESTA icon
69
Establishment Labs
ESTA
$2.72B
$5.82M 0.21%
+114,341
New +$4.59M
ALLK
70
DELISTED
Allakos
ALLK
$4.35M 0.16%
3,451,076
-219,371
-6% -$341K
XERS icon
71
Xeris Biopharma Holdings
XERS
$1.52B
$2.31M 0.08%
1,046,587
– –
ACHL
72
DELISTED
Achilles Therapeutics
ACHL
$2.01M 0.07%
1,608,089
– –
KLRS
73
Kalaris Therapeutics
KLRS
$104M
$1.44M 0.05%
82,955
– –
ADAP
74
DELISTED
Adaptimmune Therapeutics
ADAP
$1.13M 0.04%
715,607
– –
LAB icon
75
Standard BioTools
LAB
$350M
$1.12M 0.04%
+411,631
New +$994K
1 2
3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2024 Portfolio in Review

As of Q1 2024, Redmile Group held 86 positions worth $2.72B, down 2.6% from $2.8B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $452M in Q1 2024, closing 9 positions and reducing 27 holdings. Its most notable exit was Immunogen Inc, an estimated $487M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in Silence Therapeutics worth $43.8M.

  • Redmile Group's largest Q1 2024 buy was Silence Therapeutics: 2,027,669 shares worth $43.8M.
  • Redmile Group added most to Immunome in Q1 2024, an estimated $20.5M increase.
  • Redmile Group's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $31.2M.
  • Redmile Group fully exited Immunogen Inc in Q1 2024, selling an estimated $487M.
  • Redmile Group's ten largest holdings make up 42% of its $2.72B portfolio in Q1 2024.
  • Redmile Group opened 16 new positions and closed 9 in Q1 2024.
  • Redmile Group's portfolio value fell 2.6% quarter-over-quarter to $2.72B.

Based on Redmile Group's 13F filing for Q1 2024, filed 15 May 2024.